P290: Impact of concomitant 5-aminosalicylic acid therapy on vedolizumab efficacy and safety in Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Ungaro, R.(1);Kadali, H.(2);Zhang, W.(3);Adsul, S.(4);Reinisch, W.(5);
(1)The Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States;(2)Takeda, Global Patient Safety and Evaluation, Cambridge, United States;(3)Takeda, Statistical and Quantitative Science, Cambridge, United States;(4)Takeda, Global Medical Affairs, Zurich, Switzerland;(5)Medical University of Vienna, Department of Internal Medicine III, Vienna, Austria
P291: Pharmacokinetics, safety, and tolerability of etrasimod (APD334) in subjects with mild, moderate, or severe hepatic impairment: a single-dose, open-label, parallel-group studyECCO'21 VirtualYear: 2021
Authors: Lee, C.(1);Tang, Y.(1);Schroeder, C.(1);Zhang, J.(1);Nguyen-Cleary, T.(1);Mullin, S.(1);Ma, M.(1); Lyon, N.(1);Grundy, J.(1);
(1)Arena Pharmaceuticals- Inc., n/a, San Diego, United States
P292: Effect of drug therapy on the lipid profiles of patient with Inflammatory Bowel Disease: a systematic review and meta-analysisECCO'21 VirtualYear: 2021
Authors: Sleutjes, J.A.M.(1);Roeters van Lennep , J.E.(2);Boersma , E.(3);de Vries , A.C.(1);van der Woude , C.J.(1);
(1)Erasmus Medical Center, Gastroenterology & Hepatology, Rotterdam, The Netherlands;(2)Erasmus Medical Center, Internal Medicine, Rotterdam, The Netherlands;(3)Erasmus Medical Center, Clinical Epidemiology of Cardiovascular Diseases, Rotterdam, The Netherlands
P293: Local Mesenchymal Stem Cells injection in Crohn’s disease strictures: a phase I-II, open-label clinical studyECCO'21 VirtualYear: 2021
Authors: Vieujean, S.(1);Loly, J.P.(1);Boutaffala, L.(1);Pariente, B.(2);Reenaers, C.(1);Briquet, A.(3);Lechanteur, C.(3);Beguin, Y.(4);Louis, E.(1);
(1)CHU of Liège- University of Liège, Department of Gastroenterology, Liège, Belgium;(2)Hopital Claude Huriez- Université Lille 2, Department of Gastroenterology, Lille, France;(3)CHU of Liège- University of Liège, Laboratory of Cell and Gene Therapy LTCG, Liège, Belgium;(4)CHU of Liège- University of Liège, Department of Hematology, Liège, Belgium
P294: AMT-101, a gut selective oral IL-10 fusion: results from a Phase 1b study in patients with active Ulcerative ColitisECCO'21 VirtualYear: 2021
Authors: Posch, M.(1);Tanase, R.(2);Maisaia, K.(3);Jucov, A.(2);Geier, C.(1);Hotson, D.(4);Hamdy, O.(5);Whitney, J.A.(4);Garovoy, M.(6);Kanwar, B.(6);Schreiber, S.(7);
(1)Charité Research Organisation GmbH, Medicine, Berlin, Germany;(2)Arensia Exploratory Medicine- Republican Clinical Hospital 'Nicolae Testemitanu', Gastroenterology, Chisinau, Moldova- Republic Of;(3)Arensia Exploratory Medicine LLC, Gastroenterology, Tbilisi, Georgia;(4)Applied Molecular Therapeutics, Preclinical and Translational medicine, South San Francisco, United States;(5)Applied Molecular Therapeutics, Program Management, South San Francisco, United States;(6)Applied Molecular Therapeutics, Clinical Development, South San Francisco, United States;(7)University Hospital Schleswig-Holstein, Gastroenterology, Kiel, Germany
P295: Comparative Assessment of Infliximab Trough Levels between Point-of-Care Testing and current Standard of Care (enzyme linked immunosorbent assay) in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Maniero, D.(1);Lorenzon, G.(1);Marsilio, I.(1);Rigo, A.(1);Cardin, R.(1);Facchin, S.(1);Barberio, B.(1);D'Incà, R.(1);Zingone, F.(1);Bahur, B.(2);Bray, K.R.(3);Savarino, E.V.(1);
(1)University of Padova, Department of Surgery- Oncology and Gastroenterology, Padova, Italy;(2)ProciseDx, Department of Clinical Trial, San Diego, United States;(3)ProciseDx, Department of Clinical Development and Medical Affairs, San Diego, United States
P296: Stopping 5-aminosalicylic acid in patients with ulcerative colitis who are in clinical remission does not increase risks of flareECCO'21 VirtualYear: 2021
Authors: Mak, J.W.Y.(1);Yuen, N.T.K.(1);Yip, T.C.F.(1);Lam, R.H.M.(1);Lam, B.K.H.(1);Chan, F.K.L.(1);Ng , S.C.(1);
(1)The Chinese University of Hong Kong, Medicine and Therapeutics, Shatin, Hong Kong- China
P298: Budesonide MMX versus Prednisolone for Ulcerative Colitis: Comparative outcomes from a British retrospective multi-centre studyECCO'21 VirtualYear: 2021
Authors: Rosiou , K.(1);Ong Ming San , E.(1);Kumar , A.(2);Esquivel , K.(2);Almas , S.(2);Stokes , D.(2);Ng , T.(3);Jayasooriya , N.(3);Ranasinghe , I.(3);Pollok , R.(3);Brookes , M.(2);Selinger , C.P.(1);
(1)Leeds Teaching Hospitals NHS Trust, Gastroenterology, Leeds, United Kingdom;(2)The Royal Wolverhampton NHS Trust, Gastroenterology, Wolverhampton, United Kingdom;(3)St George's University Hospitals NHS Foundation Trust, Gastroenterology, London, United Kingdom
P299: Loss-of-response to anti-tumour necrosis factor-α critically depends on treatment duration in patients with Inflammatory Bowel DiseaseECCO'21 VirtualYear: 2021
Authors: Schultheiss, J.(1);Mahmoud, R.(1);Louwers, J.(1);van der Kaaij, M.(1);van Hellemondt, B.(1);van Boeckel, P.(2);Mahmmod, N.(2);Jharap, B.(3);Fidder, H.(1);Oldenburg, B.(1);
(1)University Medical Centre Utrecht, Division of Internal Medicine and Dermatology- Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(2)St. Antonius Hospital, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(3)Meander Medical Centre, Division of Internal Medicine- Department of Gastroenterology and Hepatology, Amersfoort, The Netherlands
P300: Crohn's Disease Strictures Respond to Drug Treatment and Treat-to-Target Intense Combination Therapy is More Effective than Standard Anti-TNF Therapy. The STRIDENT Randomised Controlled TrialECCO'21 VirtualYear: 2021
Authors: Schulberg, J.(1,2);Wright, E.(1,2);Holt, B.(1,2);Sutherland, T.(2,3);Ross, A.(1);Hamilton, A.(1,2);Vogrin, S.(2);Miller, A.(1);Connell, W.(1);Lust, M.(1);Ding, N.(1,2);Moore, G.(4);Bell, S.(4);Shelton, E.(4);Christensen, B.(5);De Cruz, P.(6);Rong, Y.(7);Kamm, M.(1,2);
(1)St. Vincent's Hospital Melbourne, Department of Gastroenterology, Melbourne, Australia;(2)University of Melbourne, Department of Medicine, Melbourne, Australia;(3)St. Vincent's Hospital, Department of Radiology, Melbourne, Australia;(4)Monash Health and Monash University, Department of Gastroenterology, Melbourne, Australia;(5)The Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(6)Austin Health, Department of Gastroenterology, Melbourne, Australia;(7)Latrobe Regional Hospital, Department of Gastroenterology, Traralgon, Australia STRIDENT
P301: Ustekinumab improves health-related quality of life in patients with moderate-to-severe Crohn’s disease: results up to Week 48 of the STARDUST trialECCO'21 VirtualYear: 2021
Authors: Danese, S.(1);Vermeire, S.(2);D'Haens, G.(3);Panés, J.(4);Dignass, A.(5);Magro, F.(6,7);Nazar, M.(8);Le Bars, M.(9);Lahaye, M.(10);Ni, L.(11);Bravatà, I.(12);Gaya, D.R.(13);Peyrin-Biroulet, L.(14);
(1)Humanitas University, IBD Center, Milan, Italy;(2)University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium;(3)University of Amsterdam, Academic Medical Center, Amsterdam, The Netherlands;(4)Hospital Clinic of Barcelona- IDIBAPS- CIBERehd, Department of Gastroenterology, Barcelona, Spain;(5)Agaplesion Markus Hospital, Department of Medicine I, Frankfurt/Main, Germany;(6)Institute for Molecular and Cell Biology- Faculty of Medicine University of Porto, Department of Pharmacology & Therapeutics, Porto, Portugal;(7)Hospital de São João, Department of Gastroenterology, Porto, Portugal;(8)Janssen-Cilag Polska Sp. z .o.o., Medical Affairs, Warsaw, Poland;(9)Janssen-Cilag, Medical Affairs, Issy-les-Moulineaux, France;(10)Janssen-Cilag BV, Medical Affairs, Breda, The Netherlands;(11)Janssen Cilag Russia, Medical Affairs, Moscow, Russian Federation;(12)Janssen-Cilag, Medical Affairs, Milan, Italy;(13)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(14)University Hospital of Nancy- University of Lorraine, INSERM Unité 954 and Department of Hepato-Gastroenterology, Houdemont, France
P302: Serum IL-6 is associated with treatment refractoriness in acute severe ulcerative colitisECCO'21 VirtualYear: 2021
Authors: Li Wai Suen, C.(1,2);Morris, R.(3);Choy, M.(1,2);Nigro, J.(3);Visvanathan, K.(3);De Cruz, P.(1,2);
(1)Austin Health, Department of Gastroenterology, Heidelberg, Australia;(2)Austin Academic Centre- University of Melbourne, Department of Medicine, Heidelberg, Australia;(3)St Vincent's Hospital, Immunology Research Centre, Fitzroy, Australia
P303: Local Application of Autologous Platelet-rich Plasma leads to Sustained Healing of Crohn`s Perianal Fistulae – One Year follow-up Results from a Single Center Pilot Study.ECCO'21 VirtualYear: 2021
Authors: Podmanicky, D.(1,2);Jezberova, M.(3);Lucenicova, J.(4);Bak, V.(1);Kadleckova, B.(5);Zelinkova, Z.(5);
(1)University Hospital-St Michael`s Hospital, Department of General Surgery, Bratislava, Slovakia;(2)Slovak Medical University, Faculty of Medicine, Bratislava, Slovakia;(3)Dr. Magnet ltd., Dpt of Magnetic Resonance Imaging, Bratislava, Slovakia;(4)University Hospital-St Michael`s Hospital, Laboratory of Hematology and Biochemistry-, Bratislava, Slovakia;(5)University Hospital-St Michael`s Hospital, Dpt of Gastroenterology and Digestive Endoscopy, Bratislava, Slovakia
P304: Rational infliximab induction dosing to achieve long-term deep remission in children with Inflammatory Bowel DiseasesECCO'21 VirtualYear: 2021
Authors: Kantasiripitak, W.(1);van Hoeve, K.(2);Sabino, J.(3,4);Vermeire, S.(3,4);Hoffman, I.(2);Declerck, P.(1);Thomas, D.(1);Ferrante, M.(3,4);Dreesen, E.(1,5);
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)University Hospitals Leuven, Department of Paediatric Gastroenterology Hepatology and Nutrition, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)KU Leuven, Department of Chronic Diseases Metabolism and Ageing, Leuven, Belgium;(5)Uppsala University, Department of Pharmacy, Uppsala, Sweden
P305: Effectiveness and Safety of Vedolizumab in Biologic-Naïve Patients: Real-World Data from the Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)ECCO'21 VirtualYear: 2021
Authors: Macaluso, F.(1);Fries, W.(2);Renna, S.(1);Viola, A.(2);Muscianisi, M.(2);Cappello, M.(3);Guida, L.(3);Siringo, S.(4);Camilleri, S.(5);Garufi, S.(5);Privitera, A.C.(6);Belluardo, N.(7);Giangreco, E.(7);Bertolami, C.(8);Vassallo, R.(9);Rizzuto, G.(1);Orlando, R.(1);Ventimiglia, M.(1);Orlando, A.(1);
(1)'Villa Sofia-Cervello' Hospital, IBD Unit, Palermo, Italy;(2)A.O.U. Policlinico 'G. Martino”, IBD Unit, Messina, Italy;(3)A.O.U. Policlinico “G. Giaccone”, Gastroenterology and Hepatology Unit, Palermo, Italy;(4)A.R.N.A.S. “Garibaldi”, Gastroenterology Unit, Catania, Italy;(5)A.O.O.R. “S. Elia- M. Raimondi”, Gastroenterology Unit, Caltanissetta, Italy;(6)A.O. “Cannizzaro”, Inflammatory Bowel Disease Unit, Catania, Italy;(7)A.O. “Guzzardi”, Gastroenterology Unit, Vittoria, Italy;(8)A.O.O.R. “Papardo Piemonte”, Gastroenterology Unit, Messina, Italy;(9)A.O. “Buccheri La Ferla Fatebenefratelli”, Gastroenterology and Endoscopy Unit, Palermo, Italy Sicilian Network for Inflammatory Bowel Diseases (SN-IBD)
P306: MORF-057, an oral selective α4β7 integrin inhibitor for Inflammatory Bowel Disease, leads to specific target engagement in a single and multiple ascending dose study in healthy subjectsECCO'21 VirtualYear: 2021
Authors: Ray, A.(1);Cui, D.(2);Lee, D.(2);Mangada, M.M.(1);Jones, J.(2);Bain, G.(1);Traber, P.G.(3);Vrishabhendra, L.H.(4);Krzeski, P.W.(5);Vande Casteele, N.(6,7);Reardon, M.M.(8);Stern, T.P.(9);Soo, C.L.(10);Nguyen, H.(11);Rogers, B.N.(12);Linde, P.G.(13);
(1)Morphic Therapeutic, Biology and Translation, Waltham, United States;(2)Morphic Therapeutic, Dmpk, Waltham, United States;(3)University of Pennsylvania, Medicine, Philadelphia, United States;(4)Medpace CPU, Principal Investigator, Cincinnati, United States;(5)Medpace, Medical Department, Warsaw, Poland;(6)Alimentiv, Precision Medicine, San Diego, United States;(7)University of California San Diego, Department of Medicine, La Jolla, United States;(8)Morphic Therapeutic, Pharmacovigilance, Waltham, United States;(9)Morphic Therapeutic, Biostatistics, Waltham, United States;(10)Morphic Therapeutic, Clinical Operations, Waltham, United States;(11)Morphic Therapeutic, Cmc, Waltham, United States;(12)Morphic Therapeutic, Research, Waltham, United States;(13)Morphic Therapeutic, Clinical, Waltham, United States
P307: Modelling of the relationship between ustekinumab exposure, faecal calprotectin and endoscopic outcomes in patients with Crohn’s diseaseECCO'21 VirtualYear: 2021
Authors: Wang, Z.(1);Verstockt, B.(2,3);Vermeire, S.(2,3);Sabino, J.(2,3);Ferrante, M.(2,3);Declerck, P.(1);Dreesen, E.(1,4);
(1)KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium;(2)KU Leuven, Department of Chronic Diseases- Metabolism and Ageing, Leuven, Belgium;(3)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(4)Uppsala University, Department of Pharmacy, Uppsala, Sweden
P308: Effectiveness and Safety of tofacitinib for the Treatment of Ulcerative Colitis: A Single-Arm Meta-analysis of Observational StudiesECCO'21 VirtualYear: 2021
Authors: Macaluso, F.S.(1);Maida, M.(2);Ventimiglia, M.(1);Orlando, A.(1);
(1)Ospedali Riuniti Villa Sofia-Cervello, Department of Medicine, Palermo, Italy;(2)“S.Elia-Raimondi” Hospital, Section of Gastroenterology, Caltanissetta, Italy
P309: Are results from VARSITY applicable to real world? Adalimumab versus vedolizumab as first line biological in moderate-to-severe IBD.ECCO'21 VirtualYear: 2021
Authors: Moens, A.(1,2);Verstockt, B.(1,2);Alsoud, D.(2);Sabino, J.(1,2);Ferrante, M.(1,2);Vermeire, S.(1,2);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)Catholic University Leuven, Department of Chronic diseases- Metabolism and Ageing, Leuven, Belgium
